Nanoparticles Based on Cross-Linked Poly(Lipoic Acid) Protect Macrophages and Cardiomyocytes from Oxidative Stress and Ischemia Reperfusion Injury.
Chiara BelliniSalvatore AntonucciLucía Morillas-BecerrilSara ScarpaRegina TavanoFabrizio MancinFabio Di LisaEmanuele PapiniPublished in: Antioxidants (Basel, Switzerland) (2022)
The control of radical damage and oxidative stress, phenomena involved in a large number of human pathologies, is a major pharmaceutical and medical goal. We here show that two biocompatible formulations of Pluronic-stabilized, poly (lipoic acid)-based nanoparticles (NP) effectively antagonized the formation of radicals and reactive oxygen species (ROS). These NPs, not only intrinsically scavenged radicals in a-cellular DPPH/ABTS assays, but also inhibited the overproduction of ROS induced by tert-Butyl hydroperoxide (t-BHP) in tumor cells (HeLa), human macrophages and neonatal rat ventricular myocytes (NRVMs). NPs were captured by macrophages and cardiomyocytes much more effectively as compared to HeLa cells and non-phagocytic leukocytes, eventually undergoing intracellular disassembly. Notably, NPs decreased the mitochondrial ROS generation induced by simulated Ischemia/Reperfusion Injury (IRI) in isolated cardiomyocytes. NPs also prevented IRI-triggered cardiomyocyte necrosis, mitochondrial dysfunction, and alterations of contraction-related intracellular Ca 2+ waves. Hence, NPs appear to be an effective and cardiomyocyte-selective drug to protect against damages induced by post-ischemic reperfusion.
Keyphrases
- oxidative stress
- ischemia reperfusion injury
- reactive oxygen species
- induced apoptosis
- dna damage
- endothelial cells
- high glucose
- cell cycle arrest
- cell death
- diabetic rats
- oxide nanoparticles
- induced pluripotent stem cells
- pluripotent stem cells
- healthcare
- heart failure
- drug delivery
- left ventricular
- cerebral ischemia
- angiotensin ii
- endoplasmic reticulum stress
- signaling pathway
- ionic liquid
- acute coronary syndrome
- heat shock
- single cell
- atrial fibrillation
- protein kinase